Pelisch N[au] - Search Results

Year	Number of Results
2009	2
2010	4
2011	3
2013	3
2014	1
2015	2
2017	3
2020	1
2021	2
2022	0

1

Correction to: CCL3 contributes to secondary damage after spinal cord injury.

Pelisch N, Almanza JR, Stehlik KE, Aperi BV, Kroner A. Pelisch N, et al. J Neuroinflammation. 2021 Apr 3;18(1):87. doi: 10.1186/s12974-021-02128-9. J Neuroinflammation. 2021. PMID: 33812368 Free PMC article. No abstract available.

2

CCL3 contributes to secondary damage after spinal cord injury.

Pelisch N, Rosas Almanza J, Stehlik KE, Aperi BV, Kroner A. Pelisch N, et al. J Neuroinflammation. 2020 Nov 27;17(1):362. doi: 10.1186/s12974-020-02037-3. J Neuroinflammation. 2020. PMID: 33246483 Free PMC article.

3

[Plasminogen activator inhibitor-1 (PAI-1) molecule: new physiological roles and clinical applications].

Dan T, Ichimura A, Pelisch N, Miyata K, Akahori K, Miyata T. Dan T, et al. Among authors: pelisch n. Rinsho Ketsueki. 2014 Apr;55(4):396-404. Rinsho Ketsueki. 2014. PMID: 24850450 Review. Japanese. No abstract available.

4

A novel antidiabetic therapy: free fatty acid receptors as potential drug target.

Sekiguchi H, Kasubuchi M, Hasegawa S, Pelisch N, Kimura I, Ichimura A. Sekiguchi H, et al. Among authors: pelisch n. Curr Diabetes Rev. 2015;11(2):107-15. doi: 10.2174/1573399811666150302112421. Curr Diabetes Rev. 2015. PMID: 25732031 Review.

5

RAS inhibition attenuates cognitive impairment by reducing blood- brain barrier permeability in hypertensive subjects.

Pelisch N, Hosomi N, Mori H, Masaki T, Nishiyama A. Pelisch N, et al. Curr Hypertens Rev. 2013 May;9(2):93-8. doi: 10.2174/15734021113099990003. Curr Hypertens Rev. 2013. PMID: 23971690 Review.

6

Use of a Self-Delivering Anti-CCL3 FANA Oligonucleotide as an Innovative Approach to Target Inflammation after Spinal Cord Injury.

Pelisch N, Rosas Almanza J, Stehlik KE, Aperi BV, Kroner A. Pelisch N, et al. eNeuro. 2021 Mar 11;8(2):ENEURO.0338-20.2021. doi: 10.1523/ENEURO.0338-20.2021. Print 2021 Mar-Apr. eNeuro. 2021. PMID: 33632814 Free PMC article.

7

Differential expression of ryanodine receptor isoforms after spinal cord injury.

Pelisch N, Gomes C, Nally JM, Petruska JC, Stirling DP. Pelisch N, et al. Neurosci Lett. 2017 Nov 1;660:51-56. doi: 10.1016/j.neulet.2017.09.018. Epub 2017 Sep 9. Neurosci Lett. 2017. PMID: 28899787

8

Intracellular calcium release through IP₃R or RyR contributes to secondary axonal degeneration.

Orem BC, Pelisch N, Williams J, Nally JM, Stirling DP. Orem BC, et al. Among authors: pelisch n. Neurobiol Dis. 2017 Oct;106:235-243. doi: 10.1016/j.nbd.2017.07.011. Epub 2017 Jul 12. Neurobiol Dis. 2017. PMID: 28709993

9

The toll-like receptor 2 agonist Pam3CSK4 is neuroprotective after spinal cord injury.

Stivers NS, Pelisch N, Orem BC, Williams J, Nally JM, Stirling DP. Stivers NS, et al. Among authors: pelisch n. Exp Neurol. 2017 Aug;294:1-11. doi: 10.1016/j.expneurol.2017.04.012. Epub 2017 Apr 23. Exp Neurol. 2017. PMID: 28445714

10

Angiotensin-converting enzyme inhibitor does not suppress renal angiotensin II levels in angiotensin I-infused rats.

Ohnishi K, Murase M, Nakano D, Pelisch N, Hitomi H, Kobori H, Morimoto S, Mori H, Masaki T, Ohmori K, Kohno M, Ichihara A, Nishiyama A. Ohnishi K, et al. Among authors: pelisch n. J Pharmacol Sci. 2013;122(2):103-8. doi: 10.1254/jphs.13045fp. Epub 2013 May 22. J Pharmacol Sci. 2013. PMID: 23698111 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results